A randomized, double-blind, placebo and active comparator-controlled, parallel-group study of the efficacy and safety of rivoglitazone as monotherapy treatment of type 2 diabetes mellitus.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rivoglitazone (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 27 Jul 2021 Biomarkers information updated
- 01 Nov 2012 Non-inferiority of the primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results published in the Diabetes, Obesity and Metabolism.
- 01 Nov 2012 Results published in the Diabetes, Obesity and Metabolism.